Remicade

J&J faces FTC probe on Remicade biosimilar defence

https://pharmaphorum.com/news/jj-faces-ftc-probe-on-remicade-biosimilar-defence/

J&J ends 2018 on a high, but coming year looks shaky

https://pharmaphorum.com/news/jj-ends-2018-on-a-high-but-coming-year-looks-shaky/

Stelara gains US approval for Crohn’s disease

https://pharmaphorum.com/news/stelara-crohns/

No US Remicade biosimilar until at least October

https://pharmaphorum.com/news/no-us-remicade-biosimilar-until-at-least-october/

Biosimilar switching not suitable for all patients

https://pharmaphorum.com/news/biosimilar-switching-not-suitable-patients/

Close in 10 seconds

Pharmaphorum.com

Search